Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Economic Value Of Drugs Should Be Factor In FDA Approval, More Pharma Execs Say

This article was originally published in The Pink Sheet Daily

Executive Summary

PwC Health Research Institute’s survey of 100 senior executives found 43% support FDA use of economic data in deciding whether to approve a drug, up from 14% four years ago.

You may also be interested in...

Reviewing The Reviewers: FDA Divisions Get Mixed Results In BIO Survey

FDA-sponsor interactions vary widely, but more meetings still seem to speed applications; Special Protocol Assessments fall out of favor.

Industry Skeptical Of User Fee Success, PricewaterhouseCoopers Finds

FDA may be wondering whether a lack of praise for its user fee program actually could be a criticism after a survey did not find overwhelmingly agreement the dollars were serving their intended purpose.

FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes

Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts